Krystal Biotech, Inc. (KRYS) — Fundamental Analysis

Data sourced from SEC 10-K and 10-Q filings. Most recent quarterly period ends March 31, 2026.

Snapshot & Big Picture

Krystal Biotech is a commercial-stage gene therapy company best known for Vyjuvek (beremagene geperpavec), its topical HSV-1-based gene therapy for dystrophic epidermolysis bullosa (DEB). The company transitioned from a clinical-stage biotech into a revenue-generating business at remarkable speed — annual revenue surged from roughly $50.7 million in fiscal 2023 to $290.5 million in 2024 and $389.1 million in 2025. That kind of top-line acceleration in a rare-disease gene therapy franchise is unusual, and the financial profile reflects it: low debt, strong liquidity, and rapidly expanding margins.

Latest Quarter Snapshot (Q1 2026 — Most Current Data)

The most recent filing is the 10-Q for the quarter ended March 31, 2026, filed May 4, 2026. This is more current than the annual figures and shows the momentum continuing into the new fiscal year.

A single quarter at $116.4 million in revenue annualizes to roughly $465 million, suggesting 2026 full-year revenue could meaningfully exceed 2025's $389 million if the pace holds. Operating and net margins are both above 46–48%, indicating that incremental revenue is dropping to the bottom line efficiently.

Profitability — Multi-Year Trend

The profitability story here is dramatic. In 2023, the company was still in early commercialization and posted a deeply negative operating margin of -216%, meaning operating expenses far exceeded revenue. By 2024 operating margin turned solidly positive at 22.6%, and by 2025 it reached 41.5%. The Q1 2026 operating margin of 46.1% suggests further improvement. Net margins tell a similarly strong story, aided in part by non-operating items (the 2023 net margin was positive at 21.6% despite a large operating loss, likely due to investment income or other items).

Gross margin and EBITDA figures were not available in the provided filing data for any period.

The direction is unambiguous — each successive period shows meaningful margin expansion as the fixed cost base is leveraged against growing Vyjuvek revenues.

Financial Health

Krystal's balance sheet is notably clean for a biotech. The current ratio — a measure of short-term assets versus short-term liabilities — stands at 9.46x as of Q1 2026, meaning the company holds nearly ten times more liquid assets than near-term obligations. That's a fortress-like liquidity position.

Debt-to-equity is minimal at 0.094x in the latest quarter, essentially unchanged from year-end 2025 (0.094x) and 2024 (0.116x). The company is not relying on leverage to fund its operations — it is self-financing from product revenues. This dramatically reduces financial risk relative to many commercial-stage biotechs that burn cash and carry heavy debt loads.

The decline in the current ratio from 17.76x in 2023 to the 9–10x range since is normal and healthy — in 2023 the company held proportionally more cash relative to revenue; now that cash is being deployed into operations and returned through the business cycle. Debt-to-equity has edged up modestly but remains negligible.

Growth

Revenue growth has been exceptional by any standard. From $50.7 million in FY 2023 to $290.5 million in FY 2024 represents a 473% increase year-over-year. From FY 2024 to FY 2025, growth was 34% — a significant deceleration in percentage terms but still impressive in absolute dollar magnitude ($98.6 million added). Q1 2026's $116.4 million compares favorably to Q1 2025 (implied from the $389.1 million full-year run), continuing the upward trajectory.

As the DEB patient population becomes more fully penetrated, growth rates will naturally moderate. The key question for long-term investors is whether Krystal can expand its pipeline (it has several gene therapy programs in development) to sustain growth beyond the Vyjuvek franchise.

Plain English Summary

Krystal Biotech has quietly become one of the more impressive commercial biotech stories in recent years. It took a gene therapy for a devastating rare skin disease from approval to nearly $400 million in annual revenue in roughly two years, and it did so while keeping debt almost nonexistent and maintaining a cash-rich balance sheet. Margins are expanding rapidly — the business is generating nearly 50 cents of net profit for every dollar of revenue in the most recent periods. The main risks are what you'd expect for any single-product rare-disease company: heavy dependence on Vyjuvek, the finite size of the DEB patient population, and the pressure to develop the next product before the core franchise matures. But on the numbers available, KRYS looks like a fundamentally sound, highly profitable, and financially disciplined biotech operating well within its means.

Source Filings

• Form 10-Q — Filed May 4, 2026 (Period Ended March 31, 2026)
• Form 10-K — Filed February 17, 2026 (Fiscal Year Ended December 31, 2025)